Follow the Money: Drug Discovery Robotics Lab, Clinical Sequencing Platform, More
Summary
June 29, 2022 | Funding for single-cell sequencing, small molecule drug discovery, neurological biomarkers, and more.Endpoint Health, a therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases, announced the close of $52 million in equity and debt financing. With this Series A round of financing, Watchmaker plans to accelerate investment in its protein engineering platform to deliver a suite of new products that address the demands of clinical sequencing and support emerging applications in single-cell analysis, epigenetics, and cell-free DNA. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications to improve human health, including novel therapeutics, diagnostics, synthetic biology, research tools, and agriculture. The Perelman School of Medicine at the University of Pennsylvania received a five-year, $9 million research grant from the National Cancer Institute for imaging technology that illuminates lung tumor tissue, helping clinicians detect and remove it. This technology, intraoperative molecular imaging (IMI), is based on fluorescent beacon molecules that target and bind themselves to tumor cells, essentially making them glow, allowing doctors to distinguish cancer from healthy tissue easily.